Format

Send to

Choose Destination
Nat Rev Cancer. 2009 Sep;9(9):631-43. doi: 10.1038/nrc2713.

Biological determinants of endocrine resistance in breast cancer.

Author information

1
Cancer Research Program, Garvan Institute of Medical Research, Sydney, New South Wales 2010, Australia. e.musgrove@garvan.org.au

Abstract

Endocrine therapies targeting oestrogen action (anti-oestrogens, such as tamoxifen, and aromatase inhibitors) decrease mortality from breast cancer, but their efficacy is limited by intrinsic and acquired therapeutic resistance. Candidate molecular biomarkers and gene expression signatures of tamoxifen response emphasize the importance of deregulation of proliferation and survival signalling in endocrine resistance. However, definition of the specific genetic lesions and molecular processes that determine clinical endocrine resistance is incomplete. The development of large-scale computational and genetic approaches offers the promise of identifying the mediators of endocrine resistance that may be exploited as potential therapeutic targets and biomarkers of response in the clinic.

PMID:
19701242
DOI:
10.1038/nrc2713
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center